uniQure N.V. (QURE)
NASDAQ: QURE · IEX Real-Time Price · USD
7.74
-0.06 (-0.77%)
At close: Jul 19, 2024, 4:00 PM
7.72
-0.02 (-0.26%)
Pre-market: Jul 22, 2024, 7:03 AM EDT
uniQure Revenue
uniQure had revenue of $19.00M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $8.49M with 59.34% year-over-year growth. In the year 2023, uniQure had annual revenue of $15.84M.
Revenue (ttm)
$19.00M
Revenue Growth
-82.73%
P/S Ratio
19.77
Revenue / Employee
$39,590
Employees
480
Market Cap
375.77M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
Dec 31, 2018 | 11.28M | -1.82M | -13.91% |
Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
Dec 31, 2016 | 25.10M | 14.52M | 137.27% |
Dec 31, 2015 | 10.58M | 4.44M | 72.25% |
Dec 31, 2014 | 6.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Organogenesis Holdings | 435.47M |
Revance Therapeutics | 236.65M |
Vanda Pharmaceuticals | 177.60M |
Talkspace | 162.13M |
Sight Sciences | 81.50M |
TScan Therapeutics | 14.81M |
Q32 Bio | 354.00K |
QURE News
- 9 days ago - What Led To A 150% Rise In UniQure Stock In A Week? - Forbes
- 13 days ago - uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease - GlobeNewsWire
- 21 days ago - uniQure Announces Sale of Commercial Manufacturing Facility to Genezen - GlobeNewsWire
- 21 days ago - Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA - PRNewsWire
- 7 weeks ago - uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease - GlobeNewsWire
- 2 months ago - uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 5 months ago - uniQure Announces 2023 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 7 months ago - uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease - GlobeNewsWire